



IBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US

Louvain-la-Neuve, Belgium and Yardley, Pennsylvania, USA, October 29 – IBA (Ion Beam Applications S.A., Euronext), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, and Jubilant Radiopharma, a business segment of Jubilant Pharmova Limited with the second largest network of Radiopharmacies in the United States (U.S.), are pleased to announce the signing of a contract for the installation of five Cyclone® KIUBE 180 cyclotrons and associated equipment in the U.S.

The contract will support Jubilant Radiopharma's initial \$50 million (USD) positron emission tomography (PET) radiopharmaceutical manufacturing network expansion plan. This investment, combined with the addition of the IBA RadioPharma Solutions equipment, will greatly expand Jubilant Radiopharma's capacity to produce and distribute cGMP compliant PET radiotracers across the U.S., with a particular focus in the care areas of oncology, urology, cardiology, and neurology.

The cyclotrons will be installed at Jubilant Radiopharma's PET manufacturing facilities located strategically across the U.S., bringing its total number of PET manufacturing facilities to nine. Each of the five locations will be equipped with IBA's Cyclone® KIUBE 180 cyclotron, self-shielding and targets.

The Cyclone® KIUBE is one of the most advanced cyclotrons available. It is known for its upgradability, compact design, high efficiency, and the ability to produce a wide variety of radioisotopes, making it ideal for both research and commercial production. The Cyclone® KIUBE is well-suited for producing a wide range of PET radioisotopes including Fluorine 18, Gallium 68, Zirconium 89, Carbon 11, and others, used in the diagnosis and monitoring of various medical conditions including cancer and neurological disorders.

The typical price range for a Cyclone® KIUBE and related equipment is from EUR two and a half to five million, depending on the options and configuration.

Charles Kumps, President of IBA RadioPharma Solutions, commented: *"IBA is proud to enter into this agreement with Jubilant Radiopharma to support the expansion of their radiopharmaceuticals production network in PET. This first contract demonstrates IBA's industry-leading radiopharmaceutical offering. Our cutting-edge solutions and our expertise to integrate all necessary equipment for a fully GMP compliant radiopharmacy, will accelerate Jubilant Radiopharma's expansion in all PET radioisotopes to advance nuclear medicine in US."*

Harsher Singh, CEO of Jubilant Radiopharma, stated: *"Partnering with IBA and selecting their high energy dual beam cyclotron will enable Jubilant Radiopharma to increase production capacity and serve patients across the U.S. with a variety of PET radiotracers during peak hours when they need them most."*



ENDS

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange Euronext (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Jubilant Radiopharma

Jubilant Radiopharma, a business segment of Jubilant Pharmova Limited., is an industry-leading radiopharmaceutical business that comprises development, manufacturing and commercialisation of products through Radiopharmaceuticals business and distribution through the Radiopharmacies business. Jubilant Radiopharma's manufactured products are used in the diagnosis, treatment and monitoring of various diseases with specialisation in lung, thyroid, bone and cardiac imaging products as well as in thyroid disease therapy. The division's Radiopharmacies business is the second largest radiopharmacy network in the US with 46 pharmacies distributing nuclear medicine products to the largest national Group Purchasing Organisations (GPOs), regional health systems, stand-alone imaging centres, cardiologists and hospitals. This business has over 30 years of experience in serving the US nuclear medicine community and its current geographical reach enables it to serve over four million patients yearly. The Radiopharmacies business complements the Company's niche Radiopharmaceuticals business and provides it with direct access to hospital networks. Jubilant Radiopharma is focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of "Improving Lives Through Nuclear Medicine" on a global scale.

More information can be found at: <https://www.jubilantradiopharma.com/>

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 46 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the

Press release | October 29, 2024

2



IBA | Ion Beam Applications SA

Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon

VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10

info@iba-group.com | iba-worldwide.com

Life,
Science.



Drug Discovery Services business that provides contract research and development services through two world class research centers in Bengaluru and Noida in India and the CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally.

CONTACTS

Olivier Lechien

Corporate Communication Director

+32 10 475 890

communication@iba-group.com

ICR Healthcare (Europe)

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

IBA@icrhealthcare.com

Jubilant Radiopharma, Radiopharmacies Division

Marketing Manager

Nicole Cappello

nicole.cappello@jubl.com

+1 (267) 325-4894